BioSpace News Archive

Code Biotherapeutics today announces the appointment of David Anderson, PhD, as Chief Scientific Officer.

Intrommune Therapeutics, Inc. announced the appointment of Stuart Loesch as President and Dr. William Berger as Head of Clinical Development.

IQVIA (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and contract services to the life sciences industry, today announced its Decentralized Clinical Trial (DCT) program has received GDPR compliance validation from TRUSTArc.

The latest market analysis report published by Reports and Data, titled ‘Global Netherton Syndrome Market – Forecast to 2030,’ thoroughly examines the Netherton Syndrome industry to provide essential data & information for the targeted readers

Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company committed to enabling normal lives for people with autoimmune diseases, today announced a new anti-FcRn, IMVT-1402, at Roivant’s Investor Day at 11:00am on September 28, 2022.

Synaptogenix, Inc. (Nasdaq: SNPX) (“Synaptogenix” or the “Company”), an emerging biopharmaceutical company developing regenerative therapeutics for neurodegenerative disorders, today commented on the positive Phase 3 trial results for Lecanemab announced last night by Eisai and Biogen.

Innovating and expanding diversity, equity, and inclusion in clinical trials, advancing industry solutions, and implementing technology

Wave Life Sciences Ltd. (Nasdaq: WVE) today hosted a virtual event, “Towards the Clinic: Spotlight on RNA Editing for AATD,” highlighting its WVE-006 program, which is Wave’s preclinical A-to-I RNA base editing oligonucleotide (“AIMer”) candidate for the treatment of alpha-1 antitrypsin deficiency (AATD).

Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today provided a business update and reiterated upcoming milestones.

Electromed, Inc. announced that Kathleen Skarvan, President and Chief Executive Officer, and Michelle Wirtz, Interim Chief Financial Officer, are scheduled to participate at the Issuer Direct 2022 Windy City Roundup on October 12-13, 2022.